One month after numerous companies began extensive recalls of their heartburn drugs because traces of a possible carcinogen were found in certain medicines, Sanofi (SNY) is now joining the list and recalling Zantac from the U.S. and Canada.

The move comes as regulators attempt to understand why NDMA, an organic chemical that was once used to make rocket fuel and is an unintended byproduct of certain chemical reactions, was found in some ranitidine medicines. These drugs, which are histamine-2 blockers that decrease the amount of acid created by the stomach, are sold both over the counter and by prescription.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy